WO2024079613A1 - Functionalised polymer material pad for treating skin cavity wounds - Google Patents
Functionalised polymer material pad for treating skin cavity wounds Download PDFInfo
- Publication number
- WO2024079613A1 WO2024079613A1 PCT/IB2023/060147 IB2023060147W WO2024079613A1 WO 2024079613 A1 WO2024079613 A1 WO 2024079613A1 IB 2023060147 W IB2023060147 W IB 2023060147W WO 2024079613 A1 WO2024079613 A1 WO 2024079613A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- acid
- wounds
- salts
- polyphenols
- pad according
- Prior art date
Links
- 206010052428 Wound Diseases 0.000 title claims abstract description 48
- 208000027418 Wounds and injury Diseases 0.000 title claims abstract description 45
- 239000002861 polymer material Substances 0.000 title abstract description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims abstract description 39
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 24
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 23
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 21
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 20
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 19
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 19
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 19
- 229920000615 alginic acid Polymers 0.000 claims abstract description 18
- 235000010443 alginic acid Nutrition 0.000 claims abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229920001661 Chitosan Polymers 0.000 claims abstract description 15
- 102000008186 Collagen Human genes 0.000 claims abstract description 15
- 108010035532 Collagen Proteins 0.000 claims abstract description 15
- 229920002307 Dextran Polymers 0.000 claims abstract description 15
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 15
- 229940072056 alginate Drugs 0.000 claims abstract description 15
- 229920001436 collagen Polymers 0.000 claims abstract description 15
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 14
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 14
- 230000008569 process Effects 0.000 claims abstract description 14
- 239000002253 acid Substances 0.000 claims abstract description 13
- 238000004519 manufacturing process Methods 0.000 claims abstract description 6
- 230000001338 necrotic effect Effects 0.000 claims abstract description 6
- 239000004480 active ingredient Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 28
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 13
- 206010040943 Skin Ulcer Diseases 0.000 claims description 8
- 208000002847 Surgical Wound Diseases 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 5
- 206010011985 Decubitus ulcer Diseases 0.000 claims description 4
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 4
- 208000023329 Gun shot wound Diseases 0.000 claims description 4
- 206010041899 Stab wound Diseases 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 3
- 239000000419 plant extract Substances 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims description 3
- 231100000019 skin ulcer Toxicity 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 239000001263 FEMA 3042 Substances 0.000 claims description 2
- LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 claims description 2
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 2
- 229940035676 analgesics Drugs 0.000 claims description 2
- 239000000730 antalgic agent Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 229940088597 hormone Drugs 0.000 claims description 2
- 239000005556 hormone Substances 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229960005015 local anesthetics Drugs 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000010773 plant oil Substances 0.000 claims description 2
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 2
- 229920002258 tannic acid Polymers 0.000 claims description 2
- 235000015523 tannic acid Nutrition 0.000 claims description 2
- LRBQNJMCXXYXIU-NRMVVENXSA-N tannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-NRMVVENXSA-N 0.000 claims description 2
- 229940033123 tannic acid Drugs 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 229940057838 polyethylene glycol 4000 Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 230000001954 sterilising effect Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 description 13
- 210000003491 skin Anatomy 0.000 description 12
- 210000001519 tissue Anatomy 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 229910001868 water Inorganic materials 0.000 description 10
- 230000003902 lesion Effects 0.000 description 9
- 230000017423 tissue regeneration Effects 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 8
- 230000000813 microbial effect Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 244000005700 microbiome Species 0.000 description 7
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 230000000845 anti-microbial effect Effects 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000035699 permeability Effects 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- 230000003444 anaesthetic effect Effects 0.000 description 5
- 230000000202 analgesic effect Effects 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- -1 hydrofibres Polymers 0.000 description 5
- 239000000178 monomer Substances 0.000 description 5
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000416 exudates and transudate Anatomy 0.000 description 3
- 229940074391 gallic acid Drugs 0.000 description 3
- 235000004515 gallic acid Nutrition 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011081 inoculation Methods 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000002195 synergetic effect Effects 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241001092387 Spiraea Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000223014 Syzygium aromaticum Species 0.000 description 2
- 235000016639 Syzygium aromaticum Nutrition 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000006196 deacetylation Effects 0.000 description 2
- 238000003381 deacetylation reaction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000025 haemostatic effect Effects 0.000 description 2
- 229940014041 hyaluronate Drugs 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 230000003387 muscular Effects 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009331 sowing Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- RKDVKSZUMVYZHH-UHFFFAOYSA-N 1,4-dioxane-2,5-dione Chemical class O=C1COC(=O)CO1 RKDVKSZUMVYZHH-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 235000018185 Betula X alpestris Nutrition 0.000 description 1
- 235000018212 Betula X uliginosa Nutrition 0.000 description 1
- 235000009109 Betula pendula Nutrition 0.000 description 1
- 241000219430 Betula pendula Species 0.000 description 1
- 241000978499 Brunnichia ovata Species 0.000 description 1
- 241001070941 Castanea Species 0.000 description 1
- 235000014036 Castanea Nutrition 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 240000007311 Commiphora myrrha Species 0.000 description 1
- 235000006965 Commiphora myrrha Nutrition 0.000 description 1
- 241000016649 Copaifera officinalis Species 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000238424 Crustacea Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000008960 Diabetic foot Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 244000004281 Eucalyptus maculata Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 235000007265 Myrrhis odorata Nutrition 0.000 description 1
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 1
- 206010034576 Peripheral ischaemia Diseases 0.000 description 1
- 229920005830 Polyurethane Foam Polymers 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241001278097 Salix alba Species 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229920003232 aliphatic polyester Polymers 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- KZNIFHPLKGYRTM-UHFFFAOYSA-N apigenin Chemical compound C1=CC(O)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 KZNIFHPLKGYRTM-UHFFFAOYSA-N 0.000 description 1
- 229940117893 apigenin Drugs 0.000 description 1
- XADJWCRESPGUTB-UHFFFAOYSA-N apigenin Natural products C1=CC(O)=CC=C1C1=CC(=O)C2=CC(O)=C(O)C=C2O1 XADJWCRESPGUTB-UHFFFAOYSA-N 0.000 description 1
- 235000008714 apigenin Nutrition 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 1
- MSWZFWKMSRAUBD-QZABAPFNSA-N beta-D-glucosamine Chemical compound N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O MSWZFWKMSRAUBD-QZABAPFNSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- UBAZGMLMVVQSCD-UHFFFAOYSA-N carbon dioxide;molecular oxygen Chemical compound O=O.O=C=O UBAZGMLMVVQSCD-UHFFFAOYSA-N 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000005487 catechin Nutrition 0.000 description 1
- 150000001765 catechin Chemical class 0.000 description 1
- ADRVNXBAWSRFAJ-UHFFFAOYSA-N catechin Natural products OC1Cc2cc(O)cc(O)c2OC1c3ccc(O)c(O)c3 ADRVNXBAWSRFAJ-UHFFFAOYSA-N 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000000536 complexating effect Effects 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000023753 dehiscence Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 150000002016 disaccharides Chemical group 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 235000021186 dishes Nutrition 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000001403 euterpe oleracea fruit extract Substances 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 229940094952 green tea extract Drugs 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229960002885 histidine Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 150000002515 isoflavone derivatives Chemical class 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- VUZPPFZMUPKLLV-UHFFFAOYSA-N methane;hydrate Chemical compound C.O VUZPPFZMUPKLLV-UHFFFAOYSA-N 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000008601 oleoresin Substances 0.000 description 1
- 229940114496 olive leaf extract Drugs 0.000 description 1
- 238000011369 optimal treatment Methods 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 239000011496 polyurethane foam Substances 0.000 description 1
- 229940109529 pomegranate extract Drugs 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000009877 rendering Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 229940016667 resveratrol Drugs 0.000 description 1
- 235000021283 resveratrol Nutrition 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000007151 ring opening polymerisation reaction Methods 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 230000037393 skin firmness Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 231100000216 vascular lesion Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000003253 viricidal effect Effects 0.000 description 1
- 239000002544 virustatic Substances 0.000 description 1
- 230000001790 virustatic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A61F13/01012—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/009—Materials resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/10—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing inorganic materials
- A61L2300/102—Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L2300/104—Silver, e.g. silver sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/45—Mixtures of two or more drugs, e.g. synergistic mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
- A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
- A61M35/006—Portable hand-held applicators having means for dispensing or spreading integral media using sponges, foams, absorbent pads or swabs as spreading means
Definitions
- the present invention relates to an advanced dressing, the use thereof in treating non-necrotic skin cavity wounds, and a manufacturing process thereof.
- a product which promotes the tissue repair process, protecting the wound from infection and maintaining optimal moisture and oxygen permeability of the wound microenvironment is an advanced dressing.
- Advanced dressings can be divided into:
- INTERACTIVE or ACTIVE - They play an active role in tissue repair by regulating the microenvironment of the lesion and ensuring the ideal characteristics for the repair process to be facilitated .
- wounds ulcers, and skin sores, such as diabetic ulcers, pressure ulcers and sores (bedsores), general skin ulcers and sores, surgical wounds, stab wounds, puncture wounds, gunshot wounds, burns.
- cavity wounds are deep lesions which exceed the dermo-epidermal plane and involve one or more of the following planes: subcutaneous, fascial, muscular and tendon.
- a cavity wound occurs as a result of surgical intervention (for example a surgical dehiscence, i.e., the spontaneous opening of a surgical wound after previous adhesion of the margins thereof, which may be caused by infection or maceration), trauma or a chronic ulcer (for example pressure ulcers, caused by ischaemia of the tissue planes as a result of prolonged pressure load).
- pressure ulcers are areas of tissue damage to the skin and/or underlying tissues caused primarily by pressure, stretching or friction. Although largely preventable, this type of damage (also called pressure ulcer, sore, ulcer or bedsore) is a significant phenomenon in hospital wards and in the territory, both for the number of patients involved and for the time and resources needed to treat the problem.
- Vascular lesions of the lower limbs are defined as those skin wounds of venous, arterial and/or mixed vascular aetiology, which are localized below the knee down to the foot and which last for at least eight to ten weeks.
- Chronic leg ulcers are a very frequent disease in the Western world, which mainly affects the elderly, resulting in a high social cost.
- Diabetic ulcers in particular those responsible for the diabetic foot, occur when diabetic neuropathy or lower limb arterial disease comprises the function or structure of the foot.
- the two cases also defined as neuropathic foot or ischaemic foot, are profoundly different from each other: however, in most subjects, especially of advanced age, both coexist giving rise to the so-called neuroischaemic foot.
- the surgical wound is a tissue continuity solution produced by a mechanical agent.
- two main types of surgical wounds can be found:
- Stab wounds are one of the most common household accidents and are due to sharp objects such as knives or glass. They typically appear as linear, net-margin wounds.
- Puncture wounds are due to sharp objects (daggers, nails, etc.) which cause lesions which are more developed at depth than on the surface. In addition to the entry hole, these wounds have a path which goes deep and can even take on the characteristics of penetrating or piercing wounds when the presence of an exit hole is also observed.
- Gunshot wounds are produced by projectiles (bullets or splinters) of various shapes and sizes issued by weapons or produced by the explosion of explosive devices.
- projectiles bullets or splinters
- the bullet When the bullet is animated by a very high penetration force, it can exit from the affected organism through an exit hole: this usually appears larger and more open than the entry hole because the bullet drags fragments of tissue therewith which increase the size thereof along its path.
- a burn is an acute wound of traumatic origin caused by contact with a flame, with overheated liquids or solids, chemicals, electricity, or radiant energy. Depending on the depth thereof, they are divided into 1st and 2nd superficial degree, 2nd deep degree and 3rd degree burns; the optimal treatment of the first two is the dressing which generally allows healing within two weeks; in the case of deep burns, the best treatment is surgery.
- an advanced dressing characterised by a poly (lactic-co-glycolic) acid-based polymer material pad, comprising: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate.
- the advanced dressing of the invention is a primary, nonadherent, antiseptic, hydrophobic dressing to be positioned in the wound bed, which may be associated with a secondary dressing such as a non-woven gauze, a cotton gauze, and/or a fastening system such as a self-adhering bandage or patch, and the like.
- the inventors of the present invention have surprisingly found that the above ingredients (dextran, maltodextrin, collagen, citric acid, chitosan, polyphenols, colloidal silver, hyaluronic acid and/or salts thereof, polyethylene glycol, alginate) when incorporated in a poly (lactic-co-glycolic) acid-based polymer material pad, show synergistic activity with each other in terms of low adhesiveness (rendering the dressing painless at the time of change/removal), antimicrobial power (protecting from exogenous infections), haemostatic power, stimulation of the tissue regeneration process, maintenance of optimal moisture conditions and oxygen permeability of the wound microenvironment.
- the present invention relates to an advanced dressing characterised by a pad of poly (lactic-co-glycolic) acidbased polymer material, functionalised with an active ingredient composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate, as outlined in the appended claims 1 to 8.
- the invention also relates to a process for manufacturing the advanced dressing, as outlined in the appended claim 9.
- the invention further relates to a composition
- a composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate, for use in the treatment of non-necrotic skin cavity wounds, as outlined in the appended claims 10 and 11.
- lesions which, in particular, can benefit from the application of the advanced dressing of the present invention are non-necrotic cavity wounds of the skin such as, but not limited to, diabetic ulcers, pressure ulcers and sores (bedsores), general skin ulcers and sores, surgical wounds, stab wounds, puncture wounds, gunshot wounds, burns and, in general, wounds in which the depth is such as to affect the subcutaneous, fascial, muscular and tendon planes.
- Figures 1-3 show enlarged microscopic views of a functionalised polymer material pad, in which some pores and the dimensions thereof are highlighted.
- Figure 4 shows a packaging example of the advanced dressing of the invention in a sterile vial.
- the present invention relates to a pad of poly (lactic-co-glycolic) acid-based polymer material, functionalised with an active ingredient composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate.
- said active ingredient composition is characterised by the following percentages by weight, calculated on the total weight of the mixture of said components:
- said active ingredient composition is characterised by the following percentages by weight, calculated on the total weight of the mixture of said components:
- the term "advanced cavity dressing” means an advanced dressing suitable for the treatment of skin cavity wounds.
- Primary and secondary cavity dressings exist: the primary dressings are placed and act directly on the wound bed, while the secondary dressings are used as a supplement, or for fixing the primary dressings.
- Non-limiting examples of primary dressings are alginates, hydrocolloids, hydrofibres, and polyurethane foams.
- Non-limiting examples of secondary dressings are non-woven fabric gauzes, cotton gauzes, and fastening systems such as self-adhering patches or bandages.
- active ingredient composition means a composition of substances which bring a therapeutic effect to the advanced dressing, in which preferably at least two or more substances have a synergistic effect on each other.
- the term “comprising” means that the active ingredient composition described above may contain other active substances, as will be defined below, or non-active substances, i.e., substances which do not bring a therapeutic effect to the advanced dressing.
- the advanced cavity dressing is in the form of a pad of poly (lactic-co-glycolic) acid-based polymer material, functionalised with active ingredients capable of promoting the tissue repair process, maintaining optimal moisture and oxygen permeability conditions of the wound microenvironment, preventing external microorganisms from entering by virtue of antimicrobial activity, giving haemostatic properties, and stimulating the tissue regeneration process.
- active ingredients capable of promoting the tissue repair process, maintaining optimal moisture and oxygen permeability conditions of the wound microenvironment, preventing external microorganisms from entering by virtue of antimicrobial activity, giving haemostatic properties, and stimulating the tissue regeneration process.
- the advanced cavity dressing has physical and mechanical properties such as to make it well tolerated, comfortable and non-painful, easy to apply and remove (being nonadherent to the affected tissue) or resorbable, not harmful to the wound margins.
- poly (lactic-co-glycolic) acid also known as PLGA
- PLGA poly (lactic-co-glycolic) acid
- FDA Food and Drug Administration
- PLGA degrades by hydrolysis of the ester bonds thereof in the presence of water, producing monomers of lactic acid and glycolic acid origin. Under physiological conditions, these monomers are by-products of various metabolic pathways, and there is no systemic toxicity associated with the use of PLGA for drug-delivery applications or in biomaterials. It is also possible to adjust the degradation time of the polymer by altering the ratio of the monomers used during the synthesis. This property makes it suitable and versatile in the production of biomedical devices, such as grafts, sutures, implants, prosthetic devices, surgical sealing film, micro and nanoparticles.
- the poly (lactic-co-glycolic) acid copolymer acts both as a carrier of active ingredients, regulating the release thereof to the wound site, and promoting the maintenance of optimal moisture conditions and oxygen permeability of the wound microenvironment. Moreover, the poly (lactic-co-glycolic) acid copolymer acts as a scaffold for tissue regeneration.
- poly (lactic-co-glycolic) acid-based polymer material pad means a block consisting of PLGA intended for use in padding cavity wounds, for the purpose of providing a primary dressing to the wounds themselves.
- the term "dextran” means a variety of branched glucose polymers of varying molecular weight. Dextran is characterised by a sequence of D-glucose molecules linked to each other by means of an alpha 1-6 glycosidic bond with short branches in the alpha 1-2, 1-3 and 1-4 positions. Dextran appears as a water-soluble white powder and is classified according to molecular weight. It is soluble in water and acts as a binder with the polymer.
- maltodextrin means a water-soluble complex carbohydrate. It is obtained through chemical hydrolysis processes mainly from the breakdown of starches from grains (corn, oats, wheat, rice) or tubers (potatoes, tapioca). Based on the degree of transformation of these starches, maltodextrins are created, consisting of glucose molecules arranged in polymer chains of variable length. Maltodextrin is typically composed of a variety of chains which can range from 3 to 17 glucose units.
- collagen means the body's most abundant protein, where it is concentrated primarily in the bones, tendons, cartilage, skin, membranes, and blood vessels.
- collagen is one of the main components of connective tissue.
- At the cutaneous level, collagen contributes to maintaining skin firmness, tone, and turgidity. It is present in the dermis where, together with elastic fibres and glycosaminoglycans, it gives rise to that three-dimensional structure which supports and sustains the skin, giving it strength and elasticity.
- citric acid means 2-hydroxy-l,2,3- propanetricarboxylic acid. It appears as a solid, colourless substance with a raw formula C 6 H 8 O 7 , soluble in water over a wide pH range. It can be found in fruit, especially of the genus Citrus.
- chitosan means a linear polysaccharide composed of D-glucosamine and N-acetyl-D- glucosamine, linked via ( ⁇ (1—4) bonds.
- Chitosan is usually obtained through the deacetylation of chitin, generally extracted from the exoskeleton of crustaceans (crabs, shrimps, etc.) with aqueous solution of sodium hydroxide, or it can be of vegetable or fungal origin, i.e., obtained through the deacetylation of chitin present in fungi, in which it forms the main component of the cell wall.
- Viscosity is measured in a 1% aqueous solution of acetic acid and expressed in centipoise (cP). Viscosity is measured on a Brookfield model NDJ- 1 rotational viscometer usable in a viscosity range from 10 to 100,000 cP. At room temperature, 3.0 g of test sample are taken, previously dried at constant weight at 105 ⁇ 2°C, before being placed in 300 ml of water with stirring. 3.0 g of glacial acetic acid are then added and stirring is continued for one hour until the sample is completely dissolved.
- the rotational viscometer is then used to determine the viscosity at 20 ⁇ l°C.
- the degree of acetylation is determined using NMR spectroscopy and varies between 0% and 40% while the molecular weight range varies between 3800 and 20,000 Dalton.
- polyphenols means the total amount of polyphenolic structure compounds, expressed as caffeic acid equivalents and determined analytically by the Folin-Ciocalteu method [Ainsworth EA and Gillespie KM, Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent, Nature Protocols 2007;2:875-875].
- Non-limiting examples of polyphenols are tannic acid, quercetin, apigenin, resveratrol, isoflavones, catechins.
- polyphenol sources are plant extracts such as green tea extract, chestnut, acai fruit extract, red vine extract, pomegranate extract, olive leaf extract, etc.
- colloidal silver means a compound based on silver particles. It appears as flakes or granular powder which are bright grey-black-blue in colour, substantially odourless, insoluble in alcohol and ether, slightly soluble in water.
- hyaluronic acid and “hyaluronic acid and/or salts thereof” mean a non-sulphurised glycosaminoglycan, without a protein core, with the unbranched polysaccharide chain produced by the condensation of thousands of disaccharide units formed in turn by residues of glucuronic acid and N-acetylglucosamine, linked to each other alternately by ⁇ 1-4 and ⁇ 1-3 glycosidic bonds, as well as by intramolecular hydrogen bonds, which stabilize the conformations thereof.
- the carboxyl groups of the glucuronic units are ionized, giving the hyaluronate molecule high polarity and consequently high solubility in water.
- Hyaluronate is capable of complexing with many water molecules, achieving a high degree of hydration.
- Hyaluronic acid is one of the key components of the connective tissues of man and other mammals. It gives skin the particular resistance and shape retention properties thereof.
- Hyaluronic acids of different molecular weight exist; the latter can vary from 2 to 1,500 kDa.
- Hyaluronic acids of different molecular weight show different and characteristic values of viscosity of the aqueous solutions containing it, as well as different degrees of penetration inside the skin.
- hyaluronic acid and “hyaluronic acid and/or salts thereof” mean hyaluronic acids with various molecular weights and/or salts thereof, such as, but not limited to, sodium hyaluronates, and/or mixtures of hyaluronic acids with various molecular weights and/or salts thereof.
- polyethylene glycol also known as PEG, polyethylene oxide (PEO), or polyoxyethylene (POE), IUPAC name poly (oxy-1,2-ethanedyl), a-hydro- ⁇ -hydroxyethane-1,2-diol, ethoxylate, means a polymer prepared by polymerization of ethylene oxide.
- polyethylene glycol has average molecular weight values between 300 and 10,000,000 g/mol.
- the physical properties of polyethylene glycol vary according to the average length of the macromolecules, i.e., the average number n of repetitive units, while the chemical properties remain almost unchanged.
- polyethylene glycol is liquid, while as n grows it acquires the appearance of a waxy solid with a relatively low melting point.
- PEG poly(ethylene glycol)-styrene glycol
- parenteral, topical, ophthalmic, oral and rectal pharmaceutical formulations for example as hydrophilic bases for ointments, as suspending or viscosifying agents in emulsions, in the preparation of vehicles for parenteral formulations, as plasticizers in the production of films for tablets.
- polyethylene glycol means polyethylene glycol with any molecular weight value and/or mixtures of different polyethylene glycols with different molecular weight values.
- alginate means a chemical compound consisting of an alginic acid salt.
- Alginic acid salts are, but are not limited to, sodium salts, calcium salts, and potassium salts. Alginate is extracted from the cell walls of algae and looks like a rubber. It has several uses, both in the food field
- Alginate quickly absorbs water, this property makes it useful in absorbing exudates which may be present in wounds.
- the components of the present dressing are all known and individually available on the market.
- the pad according to the invention comprises or consists of, in its entirety, 15 to 20% by weight of a substrate of poly (lactic-co-glycolic) acid and 80 to 85% by weight of the active ingredient composition.
- the active ingredient composition contains from 2 to 5% by weight of a mixture of high molecular weight and low molecular weight hyaluronic acid or sodium hyaluronate in a ratio of about 1:1.
- the polyethylene glycol is PEG 4000.
- the advanced dressing of the invention can also comprise further ingredients and excipients such as, but not limited to, local anaesthetic active ingredients, analgesic and antiinflammatory active ingredients, antimicrobial active ingredients, growth factors, cytokines, hormones, vitamins, minerals, plant extracts and oils and the like.
- Local anaesthetic active ingredients are compounds or substances of synthetic or natural origin with local anaesthetic activity.
- Non-limiting examples of synthetic local anaesthetic active ingredients are procaine, chloroprocaine, lidocaine, prilocaine, bupivacaine, ropivacaine, levobupivacaine and the like.
- Non-limiting examples of local anaesthetic active ingredients of natural origin are mint essential oil, myrrh essential oil, eucalyptus essential oil, and the like.
- Analgesic and anti-inflammatory active ingredients are compounds or substances of synthetic or natural origin with analgesic and anti-inflammatory activity.
- Non-limiting examples of synthetic analgesic and anti-inflammatory active ingredients are steroidal (for example cortisone drugs and the like) and nonsteroidal (for example NSAIDs and the like).
- Non-limiting examples of analgesic and anti-inflammatory active ingredients of natural origin are those contained in birch extracts (Betula pendula), cloves (Syzygium aromaticum), spirea (Spirea ulmaria), willow (Salix alba), and the like.
- Non-limiting examples of antimicrobial active ingredients are bacteriostatic, bactericidal, fungistatic, fungicidal, virustatic, virucidal, and similar drugs, of both synthetic and natural origin.
- Non-limiting examples of vegetable oils are essential oils with antimicrobial activity, such as tea tree oil (Melaleuca spp .), or oils with anti-inflammatory activity, such as copaiba oleoresin (Copalfera spp).
- the shape and size of the advanced dressing of the invention can take, for example, the shape of a solid, in particular a cube, a parallelepiped, a cylinder, a sphere, and the like, with the three spatial dimensions x, y, z in the range of 5 mm to 50 mm, and contains pores of 0.3 microns to 0.8 microns in diameter.
- the aforesaid advanced dressing is produced by mixing the raw materials in the amounts indicated in Table 1, placing the mixture in dies of the desired shape and size, and subjecting the mixture in the dies to freeze-drying.
- the purpose of the test is to establish whether the product in the conditions of use thereof shows efficacy in killing microbial flora.
- the activity is evaluated by contaminating the samples with a defined inoculum of selected strains of microorganisms and evaluating the killing of the contamination.
- the inoculation is performed with multiple microbial strains, Gram positive, Gram negative, yeasts, and moulds. At different but very close times, the residual microbial load for each strain is evaluated, up to 48 hours after inoculation.
- the inoculation was performed with five microbial strains at different concentrations, as shown in Table 2 below:
- the concentration of viable cells was determined by the plate count method.
- the diluent which is used is a sodium chloride- peptone solution at pH 7 with the addition of some preservative neutralizing agents (polysorbate 80, soy lecithin, L-Histidine).
- the count of the microorganisms at the different times was performed by withdrawing 1 g of product and diluting it up to lxlO 6 times. Each dilution was then plated in Petri dishes containing the agarised selective culture medium.
- the plates were incubated in a thermostat at 34 ⁇ 1°C (bacteria) or at 22 ⁇ 1°C (yeasts and moulds) for the time necessary to allow sufficient microorganism growth for counting purposes (18-24 h for bacteria, 3-7 days for yeasts and moulds).
- the CFU Coldy Forming Units
- sowing is performed at later times so as to evaluate the regression curve of microbial killing (for bacteria after 10', 2 h, 4 h; for yeasts and moulds after 30', 4 h, 8 h, 24 h and 48 h).
- Example 3 Evaluation of the release of polyphenols from an advanced dressing in the form of a functionalised polymer material pad
- the present study aimed to evaluate the release of polyphenols over time from an advanced dressing in the form of a functionalised polymer material pad.
- a dressing weighing 1.5 g was placed in a crystallizer and wet with 20 ml of water. At the times shown below, a sample of 50 microlitres was taken from the aqueous solution in contact with the dressing, and the content of total polyphenols released over time was evaluated on this sample. Such an evaluation was done by Folin-Ciocalteau assay. The times were as follows: 10 minutes, 30 minutes, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours.
- the samples were placed in transparent microplate wells.
- a gallic acid solution was placed as a positive control, with 1:1 serial dilutions going from well Al to well A6.
- lines B to H the samples taken at the different times were placed, also subjected to 1:1 serial dilutions going from well 1 to well 6.
- gallic acid concentrations expressed in mg/ml
Abstract
The present invention relates to a pad of poly(lactic-co- glycolic) acid-based polymer material, functionalised with dextran, maltodextrin, collagen, citric acid, chitosan, polyphenols, colloidal silver, hyaluronic acid and/or salts thereof, polyethylene glycol and alginate. The present invention further relates to a process for manufacturing the pad, and use of the pad in treating non-necrotic skin cavity wounds.
Description
FUNCTIONALISED POLYMER MATERIAL PAD FOR TREATING SKIN CAVITY
WOUNDS
DESCRIPTION
FIELD OF THE INVENTION
The present invention relates to an advanced dressing, the use thereof in treating non-necrotic skin cavity wounds, and a manufacturing process thereof.
BACKGROUND OF THE INVENTION
A product which promotes the tissue repair process, protecting the wound from infection and maintaining optimal moisture and oxygen permeability of the wound microenvironment is an advanced dressing.
Advanced dressings can be divided into:
PASSIVE - Used to absorb exudates and protect the lesion from external agents.
INTERACTIVE or ACTIVE - They play an active role in tissue repair by regulating the microenvironment of the lesion and ensuring the ideal characteristics for the repair process to be facilitated .
BIOACTIVE - They interact with reparative processes, releasing or forming substances which act directly on healing processes.
In the presence of certain skin lesions, the application of advanced dressings which promote healing can be useful. Lesions which may benefit from the application of advanced dressings are wounds, ulcers, and skin sores, such as diabetic ulcers, pressure
ulcers and sores (bedsores), general skin ulcers and sores, surgical wounds, stab wounds, puncture wounds, gunshot wounds, burns.
In more detail, cavity wounds are deep lesions which exceed the dermo-epidermal plane and involve one or more of the following planes: subcutaneous, fascial, muscular and tendon. Usually, a cavity wound occurs as a result of surgical intervention (for example a surgical dehiscence, i.e., the spontaneous opening of a surgical wound after previous adhesion of the margins thereof, which may be caused by infection or maceration), trauma or a chronic ulcer (for example pressure ulcers, caused by ischaemia of the tissue planes as a result of prolonged pressure load).
In particular, pressure ulcers are areas of tissue damage to the skin and/or underlying tissues caused primarily by pressure, stretching or friction. Although largely preventable, this type of damage (also called pressure ulcer, sore, ulcer or bedsore) is a significant phenomenon in hospital wards and in the territory, both for the number of patients involved and for the time and resources needed to treat the problem.
Vascular lesions of the lower limbs are defined as those skin wounds of venous, arterial and/or mixed vascular aetiology, which are localized below the knee down to the foot and which last for at least eight to ten weeks. Chronic leg ulcers are a very frequent disease in the Western world, which mainly affects the elderly, resulting in a high social cost.
Diabetic ulcers, in particular those responsible for the diabetic foot, occur when diabetic neuropathy or lower limb
arterial disease comprises the function or structure of the foot. The two cases, also defined as neuropathic foot or ischaemic foot, are profoundly different from each other: however, in most subjects, especially of advanced age, both coexist giving rise to the so-called neuroischaemic foot.
The surgical wound is a tissue continuity solution produced by a mechanical agent. In clinical practice, two main types of surgical wounds can be found:
- wounds which heal at the first attempt, in which the flaps have been brought together by applying a suture. They repair quickly, generally developing a linear scar which is often not very visible;
- wounds which heal at the second attempt, in which the flaps are not joined, often due to an infection. The healing is slow and the scar which forms can vary in size.
Stab wounds are one of the most common household accidents and are due to sharp objects such as knives or glass. They typically appear as linear, net-margin wounds.
Puncture wounds are due to sharp objects (daggers, nails, etc.) which cause lesions which are more developed at depth than on the surface. In addition to the entry hole, these wounds have a path which goes deep and can even take on the characteristics of penetrating or piercing wounds when the presence of an exit hole is also observed.
Gunshot wounds are produced by projectiles (bullets or splinters) of various shapes and sizes issued by weapons or produced by the explosion of explosive devices. When the bullet
is animated by a very high penetration force, it can exit from the affected organism through an exit hole: this usually appears larger and more open than the entry hole because the bullet drags fragments of tissue therewith which increase the size thereof along its path.
A burn is an acute wound of traumatic origin caused by contact with a flame, with overheated liquids or solids, chemicals, electricity, or radiant energy. Depending on the depth thereof, they are divided into 1st and 2nd superficial degree, 2nd deep degree and 3rd degree burns; the optimal treatment of the first two is the dressing which generally allows healing within two weeks; in the case of deep burns, the best treatment is surgery.
Various substances or products show properties useful for the regeneration of tissues affected by wounds. Moreover, several attempts are known, from products on the market or from scientific and patent literature, to associate various substances in order to try to obtain effective dressings to promote the tissue repair process, protecting against infections and maintaining the optimal microenvironment.
Although several attempts are known (from commercially available products or from scientific and patent literature) to combine various substances to try to obtain effective dressings to promote the tissue repair process, protecting against infections and maintaining optimal conditions of moisture and oxygen permeability of the wound microenvironment, the need is still felt to be able to combine different substances with different properties, in such proportions as to exhibit
synergistic effects in terms of promoting the tissue repair process, protecting against infections and maintaining optimal conditions of moisture and oxygen permeability of the wound microenvironment and at the same time able to be well tolerated and easy to apply.
In fact, there are various technical problems that an ideal advanced cavity dressing should solve. In particular, such dressings should:
- act as a vehicle for active ingredients,
- show very low toxicity/cytotoxicity towards the injured tissue in the healing phase, but be active against microorganisms, so as to ensure the control of the microbial load,
- be well tolerated, comfortable and not painful,
- be suitable for prolonged and repeated use as well,
- be easy to apply,
- not require frequent changes,
- not be adherent to the tissue of the lesion,
- be easily removable/detachable, or be resorbable,
- preserve the wound margins,
- control unpleasant odours which can come from the lesion,
- allow the gaseous exchange of oxygen, carbon dioxide and water vapour with the environment,
- be impermeable to incoming external microorganisms,
- prevent or treat infection,
- ensure mechanical protection (protect the injury from possible trauma)
- possibly, allow the monitoring of the repair process without the need to remove the dressing,
- be compatible with other possible drugs or treatments to be applied to the wound bed (for example antimicrobial drugs, analgesics, anti-inflammatory drugs, local anaesthetics, and the like), with therapies such as negative pressure and with any secondary dressings used as a supplement or for fixing primary dressings.
Overall, therefore, they should have a good compliance by the subjects who are medicated therewith, for example by providing an effective dose of several active ingredients which act in synergy, and chemical-physical, mechanical and biocompatibility features such that frequent applications are not required, i.e., preferably they are applicable once a week or less frequently.
SUMMARY OF THE INVENTION
The above object has been achieved by an advanced dressing characterised by a poly (lactic-co-glycolic) acid-based polymer material pad, comprising: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol
alginate.
The advanced dressing of the invention is a primary, nonadherent, antiseptic, hydrophobic dressing to be positioned in the wound bed, which may be associated with a secondary dressing such as a non-woven gauze, a cotton gauze, and/or a fastening system such as a self-adhering bandage or patch, and the like.
The inventors of the present invention have surprisingly found that the above ingredients (dextran, maltodextrin, collagen, citric acid, chitosan, polyphenols, colloidal silver, hyaluronic acid and/or salts thereof, polyethylene glycol, alginate) when incorporated in a poly (lactic-co-glycolic) acid-based polymer material pad, show synergistic activity with each other in terms of low adhesiveness (rendering the dressing painless at the time of change/removal), antimicrobial power (protecting from exogenous infections), haemostatic power, stimulation of the tissue regeneration process, maintenance of optimal moisture conditions and oxygen permeability of the wound microenvironment.
Therefore, the present invention relates to an advanced dressing characterised by a pad of poly (lactic-co-glycolic) acidbased polymer material, functionalised with an active ingredient composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols
colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate, as outlined in the appended claims 1 to 8.
The invention also relates to a process for manufacturing the advanced dressing, as outlined in the appended claim 9.
The invention further relates to a composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate, for use in the treatment of non-necrotic skin cavity wounds, as outlined in the appended claims 10 and 11.
In fact, lesions which, in particular, can benefit from the application of the advanced dressing of the present invention are non-necrotic cavity wounds of the skin such as, but not limited to, diabetic ulcers, pressure ulcers and sores (bedsores), general skin ulcers and sores, surgical wounds, stab wounds, puncture wounds, gunshot wounds, burns and, in general, wounds in which
the depth is such as to affect the subcutaneous, fascial, muscular and tendon planes.
The text of the appended claims forms an integral part of the present description for the purposes of evaluation of enabling disclosure.
Further features and advantages of the advanced dressing and process according to the invention will become apparent from the following description of embodiments thereof, given by way of non-limiting indication.
BRIEF DESCRIPTION OF THE DRAWINGS
Figures 1-3 show enlarged microscopic views of a functionalised polymer material pad, in which some pores and the dimensions thereof are highlighted.
Figure 4 shows a packaging example of the advanced dressing of the invention in a sterile vial.
DETAILED DESCRIPTION OF THE INVENTION
According to a first embodiment, the present invention relates to a pad of poly (lactic-co-glycolic) acid-based polymer material, functionalised with an active ingredient composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver
hyaluronic acid and/or salts thereof polyethylene glycol alginate.
According to certain embodiments of the invention, said active ingredient composition is characterised by the following percentages by weight, calculated on the total weight of the mixture of said components:
40 to 60% w/w dextran
12 to 25% w/w maltodextrin
5 to 10% w/w collagen
5 to 10% w/w citric acid
2 to 10% w/w chitosan
0.05 to 2.5% w/w polyphenols
0.001 to 0.005% w/w colloidal silver
1 to 8% w/w hyaluronic acid and/or salts thereof
1 to 5% w/w polyethylene glycol
1 to 5% w/w alginate.
According to a preferred embodiment of the invention, said active ingredient composition is characterised by the following percentages by weight, calculated on the total weight of the mixture of said components:
45 to 55% w/w dextran
15 to 20% w/w maltodextrin
6 to 9% w/w collagen
6 to 9% w/w citric acid
4 to 7% w/w chitosan
0.1 to 1% w/w polyphenols
0.001 to 0.005% w/w colloidal silver
2 to 5% w/w hyaluronic acid and/or salts thereof
2 to 4% w/w polyethylene glycol
2 to 4% w/w alginate.
As used herein, the term "advanced cavity dressing" means an advanced dressing suitable for the treatment of skin cavity wounds. Primary and secondary cavity dressings exist: the primary dressings are placed and act directly on the wound bed, while the secondary dressings are used as a supplement, or for fixing the primary dressings. Non-limiting examples of primary dressings are alginates, hydrocolloids, hydrofibres, and polyurethane foams. Non-limiting examples of secondary dressings are non-woven fabric gauzes, cotton gauzes, and fastening systems such as self-adhering patches or bandages.
As used herein, the term "active ingredient composition" means a composition of substances which bring a therapeutic effect to the advanced dressing, in which preferably at least two or more substances have a synergistic effect on each other.
As used herein, the term "comprising" means that the active ingredient composition described above may contain other active substances, as will be defined below, or non-active substances, i.e., substances which do not bring a therapeutic effect to the advanced dressing.
Preferably, the advanced cavity dressing is in the form of a pad of poly (lactic-co-glycolic) acid-based polymer material, functionalised with active ingredients capable of promoting the tissue repair process, maintaining optimal moisture and oxygen
permeability conditions of the wound microenvironment, preventing external microorganisms from entering by virtue of antimicrobial activity, giving haemostatic properties, and stimulating the tissue regeneration process.
Moreover, the advanced cavity dressing has physical and mechanical properties such as to make it well tolerated, comfortable and non-painful, easy to apply and remove (being nonadherent to the affected tissue) or resorbable, not harmful to the wound margins.
As used herein, the term "poly (lactic-co-glycolic) acid", also known as PLGA, is a copolymer which is used in many therapeutic devices approved by the Food and Drug Administration (FDA), by virtue of the biodegradability and biocompatibility thereof. It is synthesized by ring-opening copolymerization of two different monomers, the cyclic dimers (1,4-dioxane-2,5- diones) of glycolic acid and lactic acid. During polymerization, adjacent glycolic or lactic acid monomer units are linked together in the PLGA by ester bonds, thus obtaining a linear aliphatic polyester as a product. PLGA degrades by hydrolysis of the ester bonds thereof in the presence of water, producing monomers of lactic acid and glycolic acid origin. Under physiological conditions, these monomers are by-products of various metabolic pathways, and there is no systemic toxicity associated with the use of PLGA for drug-delivery applications or in biomaterials. It is also possible to adjust the degradation time of the polymer by altering the ratio of the monomers used during the synthesis. This property makes it suitable and versatile in the production
of biomedical devices, such as grafts, sutures, implants, prosthetic devices, surgical sealing film, micro and nanoparticles. In the advanced dressing of the present invention, the poly (lactic-co-glycolic) acid copolymer acts both as a carrier of active ingredients, regulating the release thereof to the wound site, and promoting the maintenance of optimal moisture conditions and oxygen permeability of the wound microenvironment. Moreover, the poly (lactic-co-glycolic) acid copolymer acts as a scaffold for tissue regeneration.
As used herein, the term "poly (lactic-co-glycolic) acid-based polymer material pad" means a block consisting of PLGA intended for use in padding cavity wounds, for the purpose of providing a primary dressing to the wounds themselves.
As used herein, the term "dextran" means a variety of branched glucose polymers of varying molecular weight. Dextran is characterised by a sequence of D-glucose molecules linked to each other by means of an alpha 1-6 glycosidic bond with short branches in the alpha 1-2, 1-3 and 1-4 positions. Dextran appears as a water-soluble white powder and is classified according to molecular weight. It is soluble in water and acts as a binder with the polymer.
As used herein, the term "maltodextrin" means a water-soluble complex carbohydrate. It is obtained through chemical hydrolysis processes mainly from the breakdown of starches from grains (corn, oats, wheat, rice) or tubers (potatoes, tapioca). Based on the degree of transformation of these starches, maltodextrins are created, consisting of glucose molecules arranged in polymer
chains of variable length. Maltodextrin is typically composed of a variety of chains which can range from 3 to 17 glucose units.
As used herein, the term "collagen" means the body's most abundant protein, where it is concentrated primarily in the bones, tendons, cartilage, skin, membranes, and blood vessels. In particular, collagen is one of the main components of connective tissue. At the cutaneous level, collagen contributes to maintaining skin firmness, tone, and turgidity. It is present in the dermis where, together with elastic fibres and glycosaminoglycans, it gives rise to that three-dimensional structure which supports and sustains the skin, giving it strength and elasticity.
As used herein, the term "citric acid" means 2-hydroxy-l,2,3- propanetricarboxylic acid. It appears as a solid, colourless substance with a raw formula C6H8O7, soluble in water over a wide pH range. It can be found in fruit, especially of the genus Citrus.
As used herein, the term "chitosan" means a linear polysaccharide composed of D-glucosamine and N-acetyl-D- glucosamine, linked via (β(1—4) bonds. Chitosan is usually obtained through the deacetylation of chitin, generally extracted from the exoskeleton of crustaceans (crabs, shrimps, etc.) with aqueous solution of sodium hydroxide, or it can be of vegetable or fungal origin, i.e., obtained through the deacetylation of chitin present in fungi, in which it forms the main component of the cell wall. The features distinguishing various types of chitosans and responsible for the different properties thereof are viscosity,
degree of acetylation and molecular weight. Viscosity is measured in a 1% aqueous solution of acetic acid and expressed in centipoise (cP). Viscosity is measured on a Brookfield model NDJ- 1 rotational viscometer usable in a viscosity range from 10 to 100,000 cP. At room temperature, 3.0 g of test sample are taken, previously dried at constant weight at 105±2°C, before being placed in 300 ml of water with stirring. 3.0 g of glacial acetic acid are then added and stirring is continued for one hour until the sample is completely dissolved. The rotational viscometer is then used to determine the viscosity at 20±l°C. The degree of acetylation is determined using NMR spectroscopy and varies between 0% and 40% while the molecular weight range varies between 3800 and 20,000 Dalton.
As used herein, the term "polyphenols" means the total amount of polyphenolic structure compounds, expressed as caffeic acid equivalents and determined analytically by the Folin-Ciocalteu method [Ainsworth EA and Gillespie KM, Estimation of total phenolic content and other oxidation substrates in plant tissues using Folin-Ciocalteu reagent, Nature Protocols 2007;2:875-875]. Non-limiting examples of polyphenols are tannic acid, quercetin, apigenin, resveratrol, isoflavones, catechins. Non-limiting examples of polyphenol sources are plant extracts such as green tea extract, chestnut, acai fruit extract, red vine extract, pomegranate extract, olive leaf extract, etc.
As used herein, the term "colloidal silver" means a compound based on silver particles. It appears as flakes or granular powder which are bright grey-black-blue in colour, substantially
odourless, insoluble in alcohol and ether, slightly soluble in water.
As used herein, the terms "hyaluronic acid" and "hyaluronic acid and/or salts thereof" mean a non-sulphurised glycosaminoglycan, without a protein core, with the unbranched polysaccharide chain produced by the condensation of thousands of disaccharide units formed in turn by residues of glucuronic acid and N-acetylglucosamine, linked to each other alternately by β1-4 and β1-3 glycosidic bonds, as well as by intramolecular hydrogen bonds, which stabilize the conformations thereof. At physiological pH, the carboxyl groups of the glucuronic units are ionized, giving the hyaluronate molecule high polarity and consequently high solubility in water. By virtue of this property, hyaluronate is capable of complexing with many water molecules, achieving a high degree of hydration. Hyaluronic acid is one of the key components of the connective tissues of man and other mammals. It gives skin the particular resistance and shape retention properties thereof. Hyaluronic acids of different molecular weight exist; the latter can vary from 2 to 1,500 kDa. Hyaluronic acids of different molecular weight show different and characteristic values of viscosity of the aqueous solutions containing it, as well as different degrees of penetration inside the skin. As used herein, the terms "hyaluronic acid" and "hyaluronic acid and/or salts thereof" mean hyaluronic acids with various molecular weights and/or salts thereof, such as, but not limited to, sodium hyaluronates, and/or mixtures of hyaluronic acids with various molecular weights and/or salts thereof.
As used herein, the term "polyethylene glycol", also known as PEG, polyethylene oxide (PEO), or polyoxyethylene (POE), IUPAC name poly (oxy-1,2-ethanedyl), a-hydro-ω-hydroxyethane-1,2-diol, ethoxylate, means a polymer prepared by polymerization of ethylene oxide. In general, polyethylene glycol has average molecular weight values between 300 and 10,000,000 g/mol. The physical properties of polyethylene glycol (such as viscosity) vary according to the average length of the macromolecules, i.e., the average number n of repetitive units, while the chemical properties remain almost unchanged. At low n values, polyethylene glycol is liquid, while as n grows it acquires the appearance of a waxy solid with a relatively low melting point. The absence of toxicity of PEG allows the use thereof in the pharmaceutical field and in particular for parenteral, topical, ophthalmic, oral and rectal pharmaceutical formulations, for example as hydrophilic bases for ointments, as suspending or viscosifying agents in emulsions, in the preparation of vehicles for parenteral formulations, as plasticizers in the production of films for tablets.
As used herein, the term "polyethylene glycol" means polyethylene glycol with any molecular weight value and/or mixtures of different polyethylene glycols with different molecular weight values.
As used herein, the term "alginate" means a chemical compound consisting of an alginic acid salt. Alginic acid salts are, but are not limited to, sodium salts, calcium salts, and potassium salts. Alginate is extracted from the cell walls of algae and
looks like a rubber. It has several uses, both in the food field
(as an emulsifying, thickening, gelling agent) and in the pharmaceutical field. Alginate quickly absorbs water, this property makes it useful in absorbing exudates which may be present in wounds.
The components of the present dressing are all known and individually available on the market.
In certain embodiments, the pad according to the invention comprises or consists of, in its entirety, 15 to 20% by weight of a substrate of poly (lactic-co-glycolic) acid and 80 to 85% by weight of the active ingredient composition.
Preferably, the active ingredient composition contains from 2 to 5% by weight of a mixture of high molecular weight and low molecular weight hyaluronic acid or sodium hyaluronate in a ratio of about 1:1.
Preferably, the polyethylene glycol is PEG 4000.
The advanced dressing of the invention can also comprise further ingredients and excipients such as, but not limited to, local anaesthetic active ingredients, analgesic and antiinflammatory active ingredients, antimicrobial active ingredients, growth factors, cytokines, hormones, vitamins, minerals, plant extracts and oils and the like.
Local anaesthetic active ingredients are compounds or substances of synthetic or natural origin with local anaesthetic activity. Non-limiting examples of synthetic local anaesthetic active ingredients are procaine, chloroprocaine, lidocaine, prilocaine, bupivacaine, ropivacaine, levobupivacaine and the
like. Non-limiting examples of local anaesthetic active ingredients of natural origin are mint essential oil, myrrh essential oil, eucalyptus essential oil, and the like.
Analgesic and anti-inflammatory active ingredients are compounds or substances of synthetic or natural origin with analgesic and anti-inflammatory activity. Non-limiting examples of synthetic analgesic and anti-inflammatory active ingredients are steroidal (for example cortisone drugs and the like) and nonsteroidal (for example NSAIDs and the like). Non-limiting examples of analgesic and anti-inflammatory active ingredients of natural origin are those contained in birch extracts (Betula pendula), cloves (Syzygium aromaticum), spirea (Spirea ulmaria), willow (Salix alba), and the like.
Non-limiting examples of antimicrobial active ingredients are bacteriostatic, bactericidal, fungistatic, fungicidal, virustatic, virucidal, and similar drugs, of both synthetic and natural origin.
Non-limiting examples of vegetable oils are essential oils with antimicrobial activity, such as tea tree oil (Melaleuca spp .), or oils with anti-inflammatory activity, such as copaiba oleoresin (Copalfera spp).
There are no particular restrictions on the shape and size of the advanced dressing of the invention, which can take, for example, the shape of a solid, in particular a cube, a parallelepiped, a cylinder, a sphere, and the like, with the three spatial dimensions x, y, z in the range of 5 mm to 50 mm, and contains pores of 0.3 microns to 0.8 microns in diameter.
EXAMPLES
Example 1 - Poly (lactic-co-glycolic) acid-based pad
An advanced dressing in the form of a functionalised polymer material pad was prepared using the following ingredients (Table 1):
The aforesaid advanced dressing is produced by mixing the raw materials in the amounts indicated in Table 1, placing the mixture in dies of the desired shape and size, and subjecting the mixture in the dies to freeze-drying.
Example 2 - Evaluation of the kinetics of killing microorganisms inoculated on the advanced dressing
The purpose of the test is to establish whether the product in the conditions of use thereof shows efficacy in killing
microbial flora. The activity is evaluated by contaminating the samples with a defined inoculum of selected strains of microorganisms and evaluating the killing of the contamination. The inoculation is performed with multiple microbial strains, Gram positive, Gram negative, yeasts, and moulds. At different but very close times, the residual microbial load for each strain is evaluated, up to 48 hours after inoculation. The inoculation was performed with five microbial strains at different concentrations, as shown in Table 2 below:
The concentration of viable cells was determined by the plate count method. The diluent which is used is a sodium chloride- peptone solution at pH 7 with the addition of some preservative neutralizing agents (polysorbate 80, soy lecithin, L-Histidine). The count of the microorganisms at the different times was performed by withdrawing 1 g of product and diluting it up to lxlO6 times. Each dilution was then plated in Petri dishes containing the agarised selective culture medium. The plates were incubated in a thermostat at 34±1°C (bacteria) or at 22±1°C
(yeasts and moulds) for the time necessary to allow sufficient microorganism growth for counting purposes (18-24 h for bacteria, 3-7 days for yeasts and moulds). By correcting the number of colonies observed for the dilution factor, the CFU (Colony Forming Units) value is obtained per gram of product.
In addition to zero-time sowing, sowing is performed at later times so as to evaluate the regression curve of microbial killing (for bacteria after 10', 2 h, 4 h; for yeasts and moulds after 30', 4 h, 8 h, 24 h and 48 h).
The results are summarized in Tables 3-6 below.
Example 3 - Evaluation of the release of polyphenols from an advanced dressing in the form of a functionalised polymer material pad
The present study aimed to evaluate the release of polyphenols over time from an advanced dressing in the form of a functionalised polymer material pad.
A dressing weighing 1.5 g was placed in a crystallizer and wet with 20 ml of water. At the times shown below, a sample of 50 microlitres was taken from the aqueous solution in contact with the dressing, and the content of total polyphenols released over time was evaluated on this sample. Such an evaluation was done by Folin-Ciocalteau assay. The times were as follows: 10 minutes, 30 minutes, 2 hours, 4 hours, 8 hours, 24 hours, 48 hours.
For the execution of the assay, the samples were placed in transparent microplate wells. In line A, a gallic acid solution was placed as a positive control, with 1:1 serial dilutions going from well Al to well A6. In lines B to H, the samples taken at the different times were placed, also subjected to 1:1 serial
dilutions going from well 1 to well 6. For the gallic acid concentrations (expressed in mg/ml), see Table 5 below.
The results are summarized in Table 6 below, in which the estimated total polyphenol concentrations (x) released from the advanced dressing at the various times are expressed as mg/ml gallic acid.
Below is an exemplary procedure for applying the dressing.
1) Prepare the wound following a standard protocol or according to the doctor's instructions.
2) Clean the wound by irrigation with a sterile saline solution. If required, remove the foreign material, cellular debris and devitalized tissue from the lesion using suitable tools, or with the aid of the mechanical action of a jet of sterile saline solution.
3) Thoroughly dry the intact skin surrounding the wound, without touching the injured skin. If necessary, shave the hair around the wound.
4) Choose an amount of advanced dressing adapted to fill the wound cavity.
5) Gently introduce the suitably cut dressing into the wound cavity, so as to fill the spaces (padding), but without exerting pressure.
6) Then, apply a secondary covering dressing on the cavity wound, with the precaution of allowing the back to be inspectable so as to ascertain the degree of saturation of the exudate, and thereby establish the time of changing the primary dressing and the secondary dressing.
Claims
1. A pad made of poly (lactic-co-glycolic) acid functionalised with an active ingredient composition comprising or consisting of: dextran maltodextrin collagen citric acid chitosan polyphenols colloidal silver hyaluronic acid and/or salts thereof polyethylene glycol alginate.
2. The pad according to claim 1, wherein the active ingredient composition is characterised by the following weight percentages, based on the total weight of the dressing:
40 to 60% w/w dextran
12 to 25% w/w maltodextrin
5 to 10% w/w collagen
5 to 10% w/w citric acid
2 to 10% w/w chitosan
0.05 to 2.5% w/w polyphenols
0.001 to 0.005% w/w colloidal silver
1 to 8% w/w hyaluronic acid and/or salts thereof
1 to 5% w/w polyethylene glycol
1 to 5% w/w alginate.
3. The pad according to claim 1, wherein the active ingredient composition is characterised by the following weight percentages, based on the total weight of the dressing:
45 to 55% w/w dextran
15 to 20% w/w maltodextrin
6 to 9% w/w collagen
6 to 9% w/w citric acid
4 to 7% w/w chitosan
0.1 to 1% w/w polyphenols
0.001 to 0.005% w/w colloidal silver
2 to 5% w/w hyaluronic acid and/or salts thereof
2 to 4% w/w polyethylene glycol
2 to 4% w/w alginate.
4. The pad according to any one of claims 1 to 3, wherein the polyphenols are tannic acid.
5. The pad according to any one of claims 1 to 4, wherein the polyethylene glycol is polyethylene glycol 4000 (PEG4000), and/or the hyaluronic acid and/or salts thereof is an approximately 1:1 mixture of low molecular weight and high molecular weight hyaluronic acid and/or sodium hyaluronate.
6. The pad according to any one of claims 1 to 5, wherein the pad is in the shape of a solid, in particular a cube, a parallelepiped, a cylinder, a sphere, and the like, with the three spatial dimensions x, y, z in the range of 5 mm to 50 mm, and contains pores of 0.3 microns to 0.8 microns in diameter.
7. The pad according to any one of claims 1 to 6 further comprising additional active ingredients selected from the group
consisting of: local anaesthetics, analgesics and antiinflammatory agents, antimicrobial agents, growth factors, cytokines, hormones, vitamins, minerals, plant extracts and oils, and the like.
8. The pad according to any one of claims 1 to 7 comprising or consisting of, in its entirety, 15 to 20% by weight of a substrate of poly (lactic-co-glycolic) acid and 80 to 85% by weight of the active ingredient composition.
9. A process for manufacturing a pad according to any one of claims 1 to 8, said process comprising the following steps:
- preparing the mixture containing the copolymer and the other active ingredients and excipients
- placing the mixture in dies with the desired shape and size
- freeze-drying the mixture in the dies
- sterilizing and packaging.
10. A composition comprising or consisting of:
40 to 60% w/w, or 45 to 55% w/w, dextran
12 to 25% w/w, or 15 to 20% w/w, maltodextrin
5 to 10% w/w, or 6 to 9% w/w, collagen
5 to 10% w/w, or 6 to 9% w/w, citric acid
2 to 10% w/w, or 4 to 7% w/w, chitosan
0,05 to 2,5% w/w, or 0,1 to 1% w/w, polyphenols
0.001 to 0.005% w/w, or 0.001 to 0.005% w/w, colloidal silver
1 to 8% w/w, or 2 to 5% w/w, hyaluronic acids and/or salts thereof
1 to 5% w/w, or 2 to 4% w/w, polyethylene glycols
1 to 5% w/w, or 2 to 4% w/w, alginate,
for use in the treatment of non-necrotic skin cavity wounds.
11. The composition for use according to claim 10, wherein the non-necrotic skin cavity wounds are selected from the group consisting of: diabetic ulcers, pressure ulcers and sores (bedsores), general skin ulcers and sores, surgical wounds, stab wounds, puncture wounds, gunshot wounds, burns.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT202200020859 | 2022-10-11 | ||
IT102022000020859 | 2022-10-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024079613A1 true WO2024079613A1 (en) | 2024-04-18 |
Family
ID=84568834
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2023/060147 WO2024079613A1 (en) | 2022-10-11 | 2023-10-10 | Functionalised polymer material pad for treating skin cavity wounds |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024079613A1 (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106139230A (en) * | 2015-04-21 | 2016-11-23 | 胡庆柳 | One has bioactive medical dressing and preparation method thereof |
US20190134252A1 (en) * | 2016-06-29 | 2019-05-09 | Arteriocyte, Inc. | Dressings comprising platelet lysate |
WO2019162928A1 (en) * | 2018-02-26 | 2019-08-29 | Fidia Farmaceutici S.P.A. | Multilayer composite material |
WO2020037211A1 (en) * | 2018-08-16 | 2020-02-20 | Abbott Nicholas L | Methods and compositions for wound healing |
US20200069478A1 (en) * | 2018-09-05 | 2020-03-05 | University Of South Carolina | Gel-Within-Gel Wound Dressing |
-
2023
- 2023-10-10 WO PCT/IB2023/060147 patent/WO2024079613A1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106139230A (en) * | 2015-04-21 | 2016-11-23 | 胡庆柳 | One has bioactive medical dressing and preparation method thereof |
US20190134252A1 (en) * | 2016-06-29 | 2019-05-09 | Arteriocyte, Inc. | Dressings comprising platelet lysate |
WO2019162928A1 (en) * | 2018-02-26 | 2019-08-29 | Fidia Farmaceutici S.P.A. | Multilayer composite material |
WO2020037211A1 (en) * | 2018-08-16 | 2020-02-20 | Abbott Nicholas L | Methods and compositions for wound healing |
US20200069478A1 (en) * | 2018-09-05 | 2020-03-05 | University Of South Carolina | Gel-Within-Gel Wound Dressing |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bano et al. | Preparation, characterization and evaluation of glycerol plasticized chitosan/PVA blends for burn wounds | |
Jones et al. | Hydrogel dressings in the management of a variety of wound types: A review | |
CN106822988B (en) | Alginate fiber functional dressing and application thereof, and alginate fiber functional dressing patch | |
CN103483625B (en) | The multi-usage biocompatible materials of absorbable and degradable | |
Moholkar et al. | Recent advances in biopolymer-based formulations for wound healing applications | |
CN110997019A (en) | Wound dressing comprising hyaluronic acid-calcium and polylysine and method for producing same | |
CN103263434B (en) | Anti-adhesion liquor for wound washing and surgery and preparation method and application of anti-adhesion liquor | |
AU2014340012B2 (en) | Chitosan paste wound dressing | |
CN107899003B (en) | Chitosan oligosaccharide medical wound care membrane and preparation method thereof | |
CN111588902A (en) | Large-area wound first-aid dressing and preparation method thereof | |
CN107261200B (en) | Chitosan-nano-laponite composite gel wound dressing and preparation method thereof | |
AU2014340012A1 (en) | Chitosan paste wound dressing | |
Kumar et al. | Recent advances in the use of algal polysaccharides for skin wound healing | |
US8303980B2 (en) | Wound-dressing material and method for manufacturing the same | |
Расулова | USE OF CHITIN AND CHITOSAN DERIVATIVES IN THE SPHERE OF PHARMACY | |
CN110038156B (en) | Hemostatic and wound healing promoting emulsion and preparation method thereof | |
CN105709273B (en) | A kind of liquid medical dressing containing polyethylene glycol | |
Valipour et al. | Preparation and characterization of wound healing hydrogel based on fish skin collagen and chitosan cross-linked by dialdehyde starch | |
CN111166932A (en) | Liquid wound spray dressing and preparation method thereof | |
WO2024079613A1 (en) | Functionalised polymer material pad for treating skin cavity wounds | |
RU2271814C2 (en) | Healing agent | |
US20230310692A1 (en) | Advanced dressing containing a polycaprolactone porous membrane | |
CN107715167A (en) | Chitosan-based hemostatic paste and preparation method as bone wax substitute | |
CN110251716B (en) | Gel dressing for wound care and preparation method thereof | |
CN113855849A (en) | Dressing composition and preparation method and application thereof |